Cargando…
Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
Background: Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, and current treatments are only partially effective in disease control. More effective combination approaches are needed to improve the survival of TNBC patients. Eribulin mesylate, a non-taxa...
Autores principales: | Xie, Xuemei, Lee, Jangsoon, Fuson, Jon A., Liu, Huey, Iwase, Toshiaki, Yun, Kyuson, Margain, Cori, Tripathy, Debu, Ueno, Naoto T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045293/ https://www.ncbi.nlm.nih.gov/pubmed/36979714 http://dx.doi.org/10.3390/biomedicines11030735 |
Ejemplares similares
-
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021) -
TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019) -
Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014) -
The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models
por: Takahashi-Ruiz, Leila, et al.
Publicado: (2022) -
ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)